In the AZA-AML-001 trial evaluating azacitidine versus conventional care regimens [10], mutations in two genes, that is FLT3 and TET2, were shown to negatively impact OS within the azacitidine treatment arm [12]. The gene discussed is FLT3; the disease is acute myeloid leukemia.